, demanding the consideration of emerging long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in combatting this disease [4] [5] [6] . Accumulating evidence demonstrates that lncRNAs have broad functional roles in the nucleus: regulation of transcriptional activation, X chromosome inactivation, heterochromatin formation, and maintenance of telomeres [7] [8] [9] [10] [11] [12] [13] [14] . Alterations of these functions promote tumour formation, progression and metastasis of many cancer types [15] [16] [17] [18] [19] [20] . However, many known lncRNAs reside either within the cytosol or shuttle between the nucleus and cytoplasm 21 , playing important roles in modulating messenger RNA translation, decay and cytoplasmic protein trafficking [22] [23] [24] . Intriguingly, many protein kinases and metabolic enzymes bind RNA through their non-canonical RNAbinding domains [25] [26] [27] , raising an important question of whether cytoplasmic lncRNAs are relevant in the regulation of fundamental cellular processes. The hypoxia-inducible factor (HIF) transcriptional program is involved in TNBC progression, recurrence and metabolic reprogramming [28] [29] [30] . Although it is well known that the hydroxylation of HIF1α mediated by proline hydroxylase domain (PHD) proteins triggers VHL-dependent HIF1α ubiquitylation and degradation under normoxic conditions 31, 32 , under certain circumstances in tumour, HIF1α can accumulate under normoxic conditions, promoting angiogenesis and cancer progression 33, 34 . However, the mechanism underlying normoxic HIF1α stabilization in TNBC remains elusive.
Here, we identified a highly prognostic lncRNA in TNBC, long intergenic non-coding RNA for kinase activation (LINK-A) (also known as LOC339535 and NR_015407), which is critical for the growth factor-induced normoxic HIF1α signalling pathway. P = 6.31 × 10 -13 P = 6.88 × 10 -6 P = 3.07 × 10 -5 P = 0.034 (Fig. 1a) . Consistently, basallike breast cancer, which lacks or shows low levels of ER, PR and HER2 proteins 35, 36 , exhibited significantly increased LINK-A expression in comparison with HER2 + , LumA, LumB and normal-like subtypes (Fig. 1b) .
LINK-A is a ∼1.5-kb-long intergenic non-protein-coding RNA (ref. 37) , which was confirmed by our northern blot and RACE analyses in MDA-MB-231 cells ( Supplementary Fig. 1a,b) . Given that LINK-A has a predicted open reading frame (ORF) of 139 amino acids, we performed in vitro translation assays, showing that neither the sense nor the antisense transcript of LINK-A encodes protein ( Supplementary Fig. 1c (Fig. 1c,d ), demonstrating the strong correlation of LINK-A expression with TNBC. Additionally, we examined the LINK-A expression level in a Duke breast cancer cohort, finding that high levels of LINK-A correlated with unfavourable recurrence-free survival for breast cancer patients (Fig. 1e) . Consistently, LINK-A was highly expressed in TNBC cell lines compared with oestrogen receptor (ER)-or HER2-positive breast cancer cell lines (Supplementary Fig. 1d ).
Next, we examined the subcellular localization of LINK-A, finding that LINK-A predominately resides in the cytoplasm or close to the cellular membrane, which was distinct from typical nuclear lncRNAs including BCAR4 (ref. 16) Fig. 1e-g ). Cell fractionation analysis showed that >90% of LINK-A is localized within the cytosolic fraction compared with the nuclear enrichment of BCAR4 ( Supplementary Fig. 1h,i) . We reasoned that LINK-A has important roles in the cytosol.
Identification and characterization of LINK-A-protein interaction
We performed an RNA pulldown assay followed by mass spectrometry 15, 16 (MS) to identify LINK-A-associated proteins that might be involved in cytoplasmic processes. Interestingly, the sense LINK-A, but not the antisense or beads control, specifically associated with two transmembrane proteins, epidermal growth factor receptor (EGFR) and transmembrane glycoprotein NMB (GPNMB), tyrosine protein kinase 6 (also known as breast tumour kinase, BRK; refs 38,39), leucine-rich repeat kinase 2 (LRRK2; refs 40, 41) , and HIF1α in the breast cancer cell (Fig. 1f, Supplementary Fig. 1j and Supplementary Table 2 ). An RNA pulldown assay in cell lysate and an RNA-protein binding assay using recombinant EGFR, BRK, LRRK2, HIF1α and GPNMB confirmed that LINK-A associated with all of the proteins mentioned above in vivo, but only BRK and LRRK2 directly interacted with LINK-A ( Supplementary  Fig. 1k-n) . The specific interaction between LINK-A and BRK or LRRK2 was also confirmed by an RNA immunoprecipitation (RIP) assay (Fig. 1g) .
To map the BRK domains required for LINK-A binding, we generated BRK SH3 (amino acids 11-72), SH2 (amino acids 78-170), kinase domains (amino acids 191-445), and regulatory carboxyterminal (amino acids 446-451) deletion mutants (Fig. 1h, bottom  panel) . Deletion of either the SH3 domain or the C-terminal region of the kinase domain of BRK alone impaired the interaction between LINK-A and BRK, suggesting that LINK-A interacts with two separate domains of BRK ( Supplementary Fig. 1o ). Double deletion of these two domains abolished the LINK-A-BRK interaction in vitro and in vivo ( Fig. 1h and Supplementary Fig. 1p ). A similar strategy was used to map the domain required for LRRK2-LINK-A interaction, showing that deletion of the WD40 domain, an atypical RNAbinding domain 16, 25 , abolished the direct interaction ( Fig. 1i and Supplementary Fig. 1q ).
To map RNA motifs essential for the LINK-A-protein interactions, we conducted an in vitro RNA-protein binding coupled with dot-blot assay 15, 16 , finding that BRK interacted with LINK-A at two regions, nucleotides 481-540 (dot B3) and nucleotides 781-840 (dot C2) (corresponding to the two domains of BRK at the SH3 domain and the C-terminal tail) (Fig. 1j) . LINK-A nucleotides 1261-1320 (dot D4) interacted with LRRK2 (Fig. 1j) . Consistently, double deletion of LINK-A (nucleotides 471-550 and nucleotides 771-850) abolished the BRK-LINK-A interaction without affecting the LRRK2-LINK-A interaction, whereas deletion of LINK-A (nucleotides 1251-1330) specifically abolished LRRK2-LINK-A association (Fig. 1k) suggesting that they contribute to specific RNA-protein interactions ( Supplementary Fig. 1r ). Supplementary Fig. 2j ), HB-EGF robustly induced the specific interaction between EGFR and GPNMB ( Fig. 2b) , indicating that EGF ligands could differentially trigger the formation of the EGFR homodimer or the heterodimer between EGFR and other receptors 45 . To test this, we performed a crosslinking assay, finding that EGF predominately triggered EGFR homodimerization with a lesser degree of EGFR:GPNMB heterodimerization but HB-EGF stimulated EGFR:GPNMB heterodimerization with less EGFR homodimerization (Fig. 2c) . Knockdown of LINK-A exhibited minimal effects on the HB-EGF-induced EGFR:GPNMB interaction as well as GPNMB phosphorylation on ligand stimulation ( Supplementary Fig. 2k ,l), suggesting that HB-EGF preferentially triggered EGFR:GPNMB heterodimer formation. We further mapped the domains mediating EGFR-GPNMB binding, and found that the kinase domain (KD) in EGFR intracellular domains (ICD) interacts with GPNMB ICD (Fig. 2d ,e and Supplementary Fig. 2m ). HB-EGF robustly induced site-specific phosphorylation of EGFR, GPNMB, BRK and HIF1α ( Fig. 2f) and pretreatment of TNBC cell lines with cetuximab impaired EGFR-GPNMB interaction ( Supplementary  Fig. 2n ,o). These observations led us to fully characterize this HB-EGF-triggered, EGFR:GPNMB-dependent signalling pathway in TNBC.
Characterization of a HB-EGF-triggered, EGFR:GPNMBdependent and LINK-A-mediated signalling pathway in TNBC
First, an in vitro kinase assay indicated that EGFR, but not BRK, phosphorylated GPNMB at Tyr 525 ( Fig. 2g ) and the exogenously expressed wild-type GPNMB but not the Y525F mutant was phosphorylated in vivo on HB-EGF stimulation (Fig. 2h) . Next, we observed the interaction between GPNMB and BRK following ligand stimulation, which was abolished in the presence of the GPNMB Y525F mutant (Fig. 2h) . Furthermore, the ligand-triggered BRK Tyr 351 phosphorylation was abolished in GPNMB Y525F-overexpressing cells (Fig. 2h) . Biochemical experiments showed that BRK SH2 domain deletion (amino acids 78-170) eliminated the ligand-dependent interaction with Tyr-525-phosphorylated GPNMB (Fig. 2i ). These data suggest that the EGFR-dependent GPNMB Tyr 525 phosphorylation is required for further recruitment of BRK through its SH2 domain and subsequent phosphorylation at Tyr 351.
LINK-A facilitates the recruitment and activation of BRK
We then conducted an immuno-RNA fluorescence in situ hybridization (FISH) assay to examine the proximity of LINK-A to the ligand-bound receptors on ligand treatment, finding the overlap between LINK-A and EGFR on HB-EGF stimulation ( Supplementary Fig. 3a) , which was further validated by in vivo RIP assay ( Supplementary Fig. 3b ). We examined the co-localization of BRK and the EGFR:GPNMB receptor complex in the presence or absence of LINK-A. Our data indicate that both BRK and phospho-BRK (Tyr 351) faithfully co-localized with EGFR on HB-EGF stimulation ( Fig. 3a and Supplementary Fig. 3c ). In contrast, depletion of LINK-A abolished the recruitment of BRK to EGFR and subsequent phosphorylation of BRK without affecting the internalization of EGFR ( Fig. 3a and Supplementary Fig. 3c ). We then performed rescue experiments in which LINK-A was knocked down by locked nucleic acids (LNAs) followed by reintroduction of LNA-resistant full-length LINK-A or one of the following deletion mutants: BRK ( 471-550 and 771-850) or LRRK2 ( 1251-1330) (Fig. 3b, lower panel, and Supplementary Fig. 3d,e) , finding that knockdown of LINK-A abolished the HB-EGF-induced BRK-GPNMB interaction, as well as BRK Tyr 351 phosphorylation (Fig. 3c,d) ; reintroduction of full-length LINK-A or LRRK2 but not the BRK mutant rescued these phenotypes (Fig. 3c,d ). These data suggest that LINK-A-BRK interaction facilitates the recruitment of BRK to the tyrosine-phosphorylated membrane receptor GPNMB, as well as subsequent autophosphorylation of BRK.
LINK-A elicits the conformational change of BRK for kinase activation
It has been reported that the activity of BRK is auto-inhibited by interaction between the SH2 domain and the Tyr-447-phosphorylated C-terminal domain [46] [47] [48] . Our data indicate that LINK-A interacts with BRK at two regions, the SH3 domain and the C-terminal domain (see Fig. 1h and Supplementary Fig. 1p ), raising a possible role for LINK-A in eliciting a BRK conformational change that mitigates the conformation required for self-inhibition. Indeed, we found that full-length LINK-A and LRRK2 LINK-A markedly enhanced the autophosphorylation and kinase activity of BRK, whereas both the control lncRNA and BRK LINK-A showed minimal effects (Fig. 3e,f) .
We next conducted a protease digestion assay by incubating BRK with caspase-1 in the presence of full-length LINK-A or BRK LINK-A, finding that caspase-1 barely cleaved BRK at amino acid 397 in the presence of an unrelated lncRNA RP11-383G10.5, but robustly cleaved BRK only in the presence of full-length LINK-A (Fig. 3g) , suggesting that a potential conformational change occurred in BRK to expose the digestion site on LINK-A binding. Notably, deletion of either of the two regions of LINK-A involved in BRK interaction failed to promote the caspase-1-dependent BRK cleavage (Fig. 3g) , suggesting that simultaneous binding of LINK-A to the two BRK domains is required to elicit the conformational change in BRK. Our data suggest that the binding of LINK-A to BRK promotes a conformational change, leading to increased accessibility of the SH2 domain and the autophosphorylation sites in the kinase domain. On ligand stimulation, these events lead to the recruitment of BRK to Tyr-525-phosphorylated GPNMB and activation of BRK on Tyr 351 phosphorylation.
LINK-A-interacting BRK and LRRK2 phosphorylate HIF1α
We next performed in vitro phosphorylation assays, finding that activated BRK phosphorylated HIF1α at Tyr 565 (Fig. 4a) and 
2,000
In vitro BRK kinase activity (pmol min -1 WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A  WT  Y565F  S797A Kinase GST BRK LRRK2 GST BRK LRRK2 GST BRK LRRK2 GST BRK LRRK2 LRRK2, another LINK-A-interacting protein kinase, phosphorylated HIF1α at Ser 797, which was further demonstrated by the marked inhibition of HIF1α phosphorylation in the presence of a S797A point mutant (Fig. 4a) . The BRK kinase activity-deficient mutant, Y351F, diminished the phosphorylation of HIF1α in vivo (Fig. 4b) . Both Tyr 565 and Ser 797 of HIF1α are conserved ( Supplementary Fig. 4a ). HB-EGF induced phosphorylation of GPNMB (Tyr 525) and BRK (Tyr 351), as well as HIF1α protein stabilization under normoxic conditions (Fig. 4c and Supplementary Fig. 4b) . Interestingly, knockdown of EGFR abolished the ligand-dependent phosphorylation of GPNMB (Tyr 525) and BRK (Tyr 351), as well as the stabilization of HIF1α; knockdown of GPNMB abolished HB-EGF-induced BRK phosphorylation and HIF1α protein stabilization, but did not affect EGFR phosphorylation (Tyr 1068) (Fig. 4d) . Knockdown of LINK-A in both MDA-MB-231 and MDA-MB-468 cells eliminated HB-EGF-induced BRK phosphorylation and HIF1α stabilization, but not phosphorylation of EGFR or GPNMB (Fig. 4e,f) . In contrast, LINK-A knockdown exhibited minimal effects on hypoxia-dependent HIF1α stabilization, and hypoxia failed to trigger phosphorylation of GPNMB and BRK (Fig. 4c-f and Supplementary  Fig. 4c ). Finally, depletion of BRK decreased ligand-triggered HIF1α protein accumulation but did not affect the phosphorylation status of EGFR or GPNMB (Fig. 4d) . Taken together, these data suggest a linear EGFR:GPNMB→LINK-A→BRK/LRRK2→HIF1α signalling cascade on HB-EGF stimulation under normoxic conditions.
On HB-EGF stimulation, HIF1α underwent Tyr 565 and Ser 797 phosphorylation but the hydroxylation at Pro 564 was inhibited, which led to HIF1α stabilization (Fig. 4g) . Knockdown of LINK-A abolished HB-EGF-induced HIF1α Tyr 565 phosphorylation and enhanced the Pro 564 hydroxylation (Fig. 4h and Supplementary  Fig. 4d) . A similar pattern was observed with EGFR, GPNMB and BRK knockdown (Fig. 4i) . These data suggest that HB-EGF triggers an lncRNA-dependent signalling pathway to stabilize HIF1α at the protein level.
Tyr 565 phosphorylation antagonizes Pro 564 hydroxylation to stabilize HIF1α under normoxia
An in vitro hydroxylation assay demonstrated that the HIF1α peptides (amino acids 557-566) but not Tyr-565-phosphorylated peptides can be hydroxylated by PHD1 (Fig. 4j and Supplementary Fig. 4e -j and Supplementary Table 3 ). An in vitro kinase assay followed by an in vitro hydroxylation assay further showed that phosphorylation of wildtype HIF1α but not the Y565F mutant by BRK prevented subsequent hydroxylation at Pro 564 (Fig. 4k) . Consistently, HB-EGF-triggered Tyr 565 phosphorylation of HIF1α and inhibition of hydroxylation at Pro 564, which was abolished by overexpression of the Y565F mutant of HIF1α (Fig. 4l) .
A cycloheximide treatment experiment revealed that on HB-EGF stimulation, the HIF1α protein exhibited ≥4 h half-life but knocking down LINK-A reduced it to 1.5 h (Supplementary Fig. 4k,l) . In TNBC cells exogenously expressing wild-type HIF1α or the Y565D mutant, the Y565D mutant exhibited a constitutively prolonged halflife ( Supplementary Fig. 4m-o) . These data indicate that LINK-Aassociated BRK phosphorylated HIF1α at Tyr 565, which prevents HIF1α hydroxylation at adjacent Pro 564 and stabilizes HIF1α under normoxia.
LINK-A-recruited LRRK2 phosphorylates Ser 797 of HIF1α to potentiate its transcriptional activity
Knockdown of LINK-A or LRRK2, or overexpression of the HIF1α S797A mutant abolished Ser 797 phosphorylation of HIF1α as well as its association with p300, which was concurrent with the release of FIH (ref. 49 ), a protein that binds to HIF1α and inhibits its transactivation function (Fig. 5a,b) . We also examined the kinase activity of LRRK2 in the presence of LINK-A, finding that full-length LINK-A, BRK LINK-A or LRRK2 LINK-A exhibited minimal effect on the kinase activity of LRRK2 (Supplementary Fig. 5a ). The rescue experiments indicated that full-length LINK-A fully rescued HIF1α phosphorylation and protein stabilization; BRK LINK-A rescued only HIF1α Ser 797 phosphorylation and LRRK2 LINK-A restored HIF1α Tyr 565 phosphorylation and protein stabilization, but failed to rescue the phosphorylation of HIF1α at Ser 797 (Fig. 5c) . Recent studies have shown that certain lncRNAs encode small protein peptides [50] [51] [52] . Whereas our data have demonstrated that a predicted ORF of LINK-A has no protein-coding products in vitro (see Supplementary Fig. 1a-c) , we further mutated the predicted translational start codon ATG (nucleotides 318-321), or the potential stop codon TGA (nucleotides 732-735), of this ORF in a functional rescue experiment, finding that the phosphorylation of BRK (Tyr 351) and HIF1α (Tyr 565), two major cellular effects mediated by LINK-A, was fully rescued by wild-type LINK-A as well as ATG→TAG or TGA→TGT mutants of LINK-A ( Supplementary Fig. 5b-d ). These observations suggested that the cellular effect of LINK-A is mainly dependent on its RNA function instead of the potential translational products. Taken together, we demonstrated that LINK-A, in coordination with two protein kinases BRK and LRRK2, mediated a growth factor-triggered signalling cascade to synergistically regulate the phosphorylation and protein stabilization of HIF1α under normoxia.
LINK-A-dependent normoxic HIF1α signalling promotes tumour growth and correlates with TNBC
Next, we examined the transcriptional activity of HIF1α on HB-EGF stimulation by ChIP-seq, finding that under normoxia, HB-EGF triggered the recruitment of HIF1α to the promoters of HIF1α target genes and regulated the HIF1α-dependent transcriptional program (Fig. 5d ,e and Supplementary Table 4 ). Knockdown of LINK-A in TNBC cells impaired HIF1α-target gene expression on HB-EGF stimulation (Fig. 5f,g and Supplementary Fig. 5e ). Consistently, in vitro glucose uptake and lactate production assays confirmed that LINK-A deficiency impaired glycolysis ( Supplementary Fig. 5f-l) . Consistent with the in vitro colony formation assays (Fig. 5h) , mice with xenografts of LINK-A-depleted tumour cells rarely developed tumour mass in vivo (Fig. 5i,j and Supplementary Fig. 5m) .
The LINK-A-mediated signalling pathway was also activated in TNBC tissues, as evidenced by a significantly higher staining density of phospho-GPNMB (Tyr 525), phospho-BRK (Tyr 351), phospho-HIF1α (Tyr 565) and phospho-HIF1α (Ser 797) in TNBC samples compared with non-TNBC samples (Fig. 6a-c and Supplementary  Fig. 6a ). Furthermore, within the TNBC category, breast cancer with advanced lymph-node metastasis showed increased phospho-BRK (Tyr 351), phospho-HIF1α (Tyr 565) and phospho-GPNMB (Tyr 525) levels compared with tissue samples with no lymph-node metastasis (Fig. 6a-c,d-f, upper panel) . Importantly, there is a strong correlation 
MDA-MB-231 * * * * * * * * * * NS Data are mean ± s.e.m., n = 5 mice per group ( * * P < 0.01, two-tailed paired Student's t-test). Unprocessed original scans of blots are shown in Supplementary Fig. 7 . between LINK-A expression and the phosphorylation status of BRK, HIF1α and GPNMB in these TNBC tissues (Fig. 6d-f, lower panel) , and breast cancer patients with higher levels of these phosphoproteins exhibited a shorter survival time (Fig. 6g-i) . Furthermore, the TCGA database revealed that both BRK and LRRK2 are highly expressed in invasive breast carcinoma (Supplementary Fig. 6b ). Our data implicate LINK-A and its associated signalling pathway as potential biomarkers and therapeutic targets for TNBC.
DISCUSSION
Our study reveals that lncRNA directly interacts with non-receptor tyrosine kinase and facilitates its recruitment to the membrane-bound receptor complex and subsequent activation on ligand stimulation, broadening the known mechanisms of lncRNA action (Fig. 6j) . The regulatory mechanism of non-receptor tyrosine kinase activation is largely unknown. We propose a model in which LINK-A interacts with non-receptor tyrosine kinases to facilitate their activation. At the basal level, BRK, a prototype RNA-binding non-receptor tyrosine kinase, is in a 'closed' conformation and its kinase activity is auto-inhibited, mediated by the self-inhibitory interaction between the SH2 domain and the phospho-C-terminus (Tyr 447; ref. 46) . The binding of LINK-A to both the SH3 domain and the C-terminal region of BRK leads to a more accessible structure of BRK, which may contribute to higher accessibility by other regulatory proteins and kinases for its activation. Most common cancer types show increased HIF1α protein levels although hypoxic areas are missing 53, 54 . Our study delineates an lncRNA-protein kinase module that regulates normoxic HIF1α stabilization with respect to functional implications in glycolytic reprogramming and tumorigenesis. The LINK-A-dependent HIF1α signalling cascade and the consequent effects on cancer cell glycolysis implicate LINK-A and LINK-A-interacting kinases/receptors as promising therapeutic targets for TNBC. Analyses of the LINK-A expression status in the TCGA database and breast cancer tissues both indicated that LINK-A significantly correlates with TNBC, revealing an lncRNA that can serve as a biomarker for further classification of TNBC.
Our study identifies four previously unknown phosphorylation sites of GPNMB, BRK and HIF1α in a LINK-A-regulated signalling pathway for glycolysis reprogramming in TNBC. These phosphorylation events predict a worse outcome in TNBC patients, suggesting that the LINK-A-dependent signalling pathway plays a critical role in TNBC and may provide wide-ranging therapeutic targets for treating TNBC.
METHODS
Methods and any associated references are available in the online version of the paper. Cell culture, transfection and lentiviral transduction. Human breast cancer, human mammary gland epithelia, and human embryonic kidney cell lines were purchased from the American Type Culture Collection (ATCC) and the Characterized Cell Line Core Facility (MD Anderson Cancer Center). siRNA and plasmid transfections were performed using DharmaFECT4 (Thermo Scientific) and Lipofectamine 3000 (Life Technologies). Lentiviruses were produced in HEK293T cells with the ViraPower Lentiviral Expression System. All of the cell lines were free of mycoplasma contamination (tested by the vendors using the MycoAlert kit from Lonza). No cell lines used in this study are found in the database of commonly misidentified cell lines (ICLAC and NCBI Biosample) based on short tandem repeats (STR) profiling performed by vendors.
Cell treatments, crosslinking, fractionation, cell lysis, immunoprecipitation and immunoblotting. Cells were serum starved overnight followed by growth factor (Peprotech) treatment for 30 min at the following concentrations: EGF (10 ng ml −1 ), amphiregulin (10 ng ml −1 ), betacellulin (10 ng ml −1 ), epigen (200 ng ml −1 ), epiregulin (10 ng ml −1 ), HB-EGF (10 ng ml −1 ), heregulin-β1 (5 ng ml −1 ), TGF-α (2 ng ml −1 ). Cetuximab (20 µg ml −1 ) was provided by S. Kopetz (MD Anderson Cancer Center, USA). Chemical crosslinking was carried out as previously described 55 with 1 mM 3,3 -dithiobis(sulphosuccinimidylpropionate) (DTSSP; Pierce). In certain experiments, cells were pre-treated with 10 µM InSolution MG-132 (EMD Millipore) for 6 h before growth factor treatment. Nuclear/cytoplasmic fractionation, cell lysis, immunoprecipitation and immunoblotting were performed as previously described 16 .
RNA preparation, northern blot and RACE analysis. RNA in vitro transcription and purification were performed as previously described 16 . Total RNAs from 1 × 10 6 MDA-MB-231 cells with or without HB-EGF treatment were analysed for LINK-A and β-actin expression using biotin-labelled LNA probes (Exiqon, sequence are listed in the Oligonucleotide sequences, probes and primers section) according to the NorthernMax Kit (Ambion). RACE-PCR was performed using SMARTer RACE 5 /3 Kit (Clontech).
Cloning procedures. Full-length LINK-A and deletion mutants were constructed by subcloning the gene sequences into pCDNA3.1 (+) backbone (Life Technologies).
To generate the LNA no. 5-resistant LINK-A mammalian expression vectors used in the rescue experiments, the LNA no. 5 targeting sequence ACA GCT CAT TTA TCC A was mutated to ACA GGC GAT TTA TCC A. The full-length HIF1α, GPNMB, BRK and LRRK2 mammalian expression vectors were obtained from Origene and Addgene. His-tagged full-length EGFR, extracellular domain (ECD) and intracellular domain (ICD) were provided by M.-C.H. FLAG-tagged full-length GPNMB, ECD + transmembrane domain (TM), and ICD + TM were constructed by subcloning the corresponding gene sequences into an SFB-tagged expression vector (provided by J. Chen, MD Anderson Cancer Center, USA) using the Gateway system (Life Technologies).
Bacterial expression vectors for His-tagged HIF1α and GPNMB ICD were constructed by subcloning the corresponding gene sequences into the pET-DEST42 vector. GST-tagged BRK (WT and mutants) was constructed into the pGEX-5X-1 backbone (GE Healthcare). GST-tagged EGFR ICD, EGFR kinase domain (KD), and EGFR C-terminal domain (CTD) in the pGEX-6p-1backbone were provided by M.-C.H.
All single-point and deletion mutations were generated using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Protein recombination, purification and in vitro translation. Recombinant proteins were expressed in the Escherichia coli strain BL21-CodonPlus (DE3)-RIPL (Agilent Technologies) and purified using the Protein Purification Kit (Clontech). Recombinant Flag-GPNMB and PHD1 were purchased from Origene. GST-EGFR was purchased from Active Motif; HIF1α and BRK were purchased from Novus Biologicals. LRRK2 was purchased from SignalChem. Recombinant active caspase-1 was purchased from R&D Systems. In vitro translation of LINK-A was conducted using TnT Quick Coupled Transcription/Translation Kit and detection was performed using the Transcend Non-Radioactive Translation Detection System (Promega).
RNA pulldown, mass spectrometry analysis, in vitro RNA-protein binding assay and in vitro RNA-protein binding coupled with dot-blot assay. The cell lysates were freshly prepared using the ProteoPrep Zwitterionic Cell Lysis Kit, Mass Spec Grade (Protea) with Anti-RNase, Protease/Phosphatase Inhibitor Cocktail, Panobinostat and Methylstat supplemented in the lysis buffer. The BcMag Monomer avidin Magnetic Beads (Bioclone) were first prepared according to the manufacturer's instructions and then immediately subjected to RNA (20 µg) capture in RNA capture buffer (20 mM Tris-HCl pH 7.5, 1 M NaCl, 1 mM EDTA) for 30 min at room temperature with agitation. The RNA-captured beads were washed once with NT2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 0.05% NP-40) and incubated with 30 mg cell lysates diluted in NT2 buffer supplemented with 50 U ml −1 Anti-RNase, 2 mM dithiothreitol, 30 mM EDTA and Heparin 0.02 mg ml −1 for 4 h at 4 • C with rotation. The RNA-binding protein complexes were washed sequentially with NT2 buffer (twice), NT2-high-salt buffer containing 500 mM NaCl (twice), NT2-high-salt buffer containing 1 M NaCl (once), NT2-KSCN buffer containing 750 mM KSCN (twice) and PBS (once) for 5 min at 4 • C and eluted by 2 mM D-biotin in PBS. The eluted protein complexes were denatured, reduced, alkylated and digested with immobilized trypsin (Promega) for MS analysis at MD Anderson Cancer Center Proteomics Facility. The RNA-protein binding assays and in vitro RNA-protein binding coupled with dot-blot assay were performed as described previously 16 .
RNAScope assay, RNA FISH, immunofluorescence and immunohistochemistry. RNAScope assay and RNA FISH were performed as previously described 16 . RNAScope probes targeting LINK-A (Cat. no. 412027), BCAR4 (Cat. no. 407777) or HOTAIR (Cat. no. 312347) were custom designed or purchased from Advanced Cell Diagnostics. LNA FISH probes targeting LINK-A and a control probe targeting β-actin (300512-04) were purchased from Exiqon (sequences are listed in the Oligonucleotide sequences, probes and primers section).
For immuno-RNA FISH, the slide from RNA FISH was further blocked with blocking buffer (1 × PBS, 5% BSA, 0.3% Triton X-100) for 1 h at room temperature followed by incubation with primary antibodies (diluted 1:200) for 1 h at room temperature. After incubation with fluorochrome-conjugated secondary antibodies for 1 h at room temperature in the dark, the slide was washed and mounted for detection. Immunofluorescence and immunohistochemistry were performed as previously described 16 . The quantification of RNAScope staining densities was measured by RNAscope SpotStudio v1.0 Software (Advanced Cell Diagnostics). The quantification of IHC DOI: 10.1038/ncb3295 staining density was performed by Image-Pro plus 6.0 (Media Cybernetics) and calculated on the basis of the average staining intensity and the percentage of positively stained cells.
Computational analysis of TCGA RNA-Seq data. Breast cancer RNA-seq BAM files was downloaded from UCSC Cancer Genomics Hub (CGHub, https://cghub. ucsc.edu). TCGA BAM files were generated based on the MapSplice algorithm for alignment against the hg19 reference genome using default parameters 56 . We then quantified lncRNA expression of LINK-A as RPKM (reads per kilobase per million mapped reads 57 ) as previously described 58 , and the analysis was based on log 2 (RPKM+1). Clinical information, PAM50 subtype, and ER, PR and HER2 status were obtained from the TCGA marker paper 1 . We used analysis of variance (ANOVA) or Student's t-test to detect the statistical difference between two or more groups.
In vitro kinase assay. Wild-type or mutant substrate proteins were incubated with 50 µl of in vitro kinase assay buffer II (SignalChem) containing 100 µM ATP (cold reaction) or 10 µCi [γ- 32 P]ATP and the indicated protein kinase for 1 h at 30 • C. Resulting products were separated by SDS-PAGE and detected by Coomassie blue staining, autoradiography or immunoblotting with phospho-specific antibodies. The specific BRK and LRRK2 kinase activities were measured using a Universal Kinase Activity Kit (R&D Systems).
In vitro HIF1α hydroxylation assay. Five micrograms of wild-type His-tagged HIF1α or the Y565F mutant was incubated with 1 µg recombinant PHD1 in a reaction buffer containing 10 µM FeSO 4 , 100 µM 2-oxo-glutarate, 1 mM ascorbate, 100 µM dithiothreitol, and 50 µM Tris-HCl (pH 7.8) at 37 • C for 1 h. HIF1α hydroxylation was analysed by SDS-PAGE and immunoblotting with specific antibody against Pro 564 hydroxylation. For the quantitative peptide hydroxylation assay, 10 µg synthesized unmodified peptide (LDLEMLAPYI) or Tyr-565-phosphopeptide (LDLEMLAP-pY-I) and 3 µg recombinant PHD1 were incubated in the same reaction buffer described above or in the same buffer, except containing 100 µM DMOG. Resulting peptides were purified by ZipTip and analysed by liquid chromatography coupled with tandem MS (LC-MS) to confirm the presence of the proline-hydroxylated peptides. The acquired MS/MS data were searched against a database to identify hydroxylated proline sites through a dynamic mass shift for the modified proline (+15.9949 Da).
Chromatin immunoprecipitation (ChIP), RNA immunoprecipitation (RIP), ChIP-seq and data analysis. ChIP and RIP were performed as previously described 16 . ChIP-seq and data analysis were performed by ArrayStar. The mapped reads were used for peak detection by MACS v1.4.0 (Model-based Analysis of ChIPSeq) software. Statistically significant ChIP-enriched regions (peaks) were identified by comparison to a Poisson background model (Cutoff P value = 10 −4 ).
Anchorage-independent growth assay, glucose uptake assay and lactate production assay. The anchorage-independent growth assay was performed as previously described 59 . Glucose uptake and lactate production assays were performed using the Glucose Uptake Cell-based Assay Kit and the L-Lactate Assay Kit (Cayman Chemical) respectively. Lactate production was expressed as lactate concentration per 10 4 viable cells.
In vivo tumorigenesis study. All animal experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. Animals arriving in our facility were randomly put into cages with five mice each. They were implanted with respective tumour cells in the unit of cages, which were randomly selected. The animal experiment was set up to use 5 mice per group to detect a twofold difference with power of 80% and at the significance level of 0.05 by a two-sided test for significant studies. Tumour cells in 30 µl growth medium (mixed with Matrigel at a 1/1 ratio) were injected subcutaneously into the flank of six-to eight-week-old female nude mice. Tumour size was measured every five days using a calliper, and tumour volume was calculated using the standard formula: 0.54 ×L × W 2 , where L is the longest diameter and W is the shortest diameter. The tumours were removed, photographed and weighed. The investigators were not blinded to allocation during experiments and outcome assessment. Supplementary Figure 7 Uncropped images for IB detection. 
